Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing

Nature Communications

Volumn 5, Issue , 2014, Pages

  Adachi, Kei ^a   Enoki, Tatsuji ^b   Kawano, Yasuhiro ^a,b   Veraz, Michael ^a   Nakai, Hiroyuki ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b TAKARA BIO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GALACTOSE; NEUTRALIZING ANTIBODY; VIRUS DNA; HOMEODOMAIN PROTEIN; RAG-1 PROTEIN;

AMINO ACID; BLOOD; GENE EXPRESSION; PHENOTYPE; PROTEIN; VIRUS;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BARCODING; DNA LIBRARY; EPITOPE MAPPING; FEMALE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; PLASMA CLEARANCE; RECEPTOR BINDING; VIRAL CLEARANCE; VIRAL TROPISM; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; KNOCKOUT MOUSE; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYSIOLOGY; PROCEDURES;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CAPSID; CELL LINE; DEPENDOVIRUS; DNA BARCODING, TAXONOMIC; DNA, VIRAL; GENETIC THERAPY; GENETIC VECTORS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE;

EID: 84904908113     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4075     Document Type: Article

References (61)

1. Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347 (2006).
2. Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365 (2011).
3. Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-712 (2010).
4. Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. & Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381-390 (2009).
5. Asokan, A., Schaffer, D. V. & Samulski, R. J. The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699-708 (2012).
6. Shen, S. et al. Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J. Virol. 86, 10408-10417 (2012).
7. Opie, S. R., Warrington, Jr. K. H., Agbandje-McKenna, M., Zolotukhin, S. & Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995-7006 (2003).
8. Kern, A. et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072-11081 (2003).
9. Bell, C. L., Gurda, B. L., Van Vliet, K., Agbandje-McKenna, M. & Wilson, J. M. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J. Virol. 86, 7326-7333 (2012).
10. Wu, Z. et al. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80, 11393-11397 (2006).
11. Wu, P. et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647 (2000).
12. Salganik, M. et al. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J. Virol. 86, 11877-11885 (2012).
13. Raupp, C. et al. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J. Virol. 86, 9396-9408 (2012).
14. Pulicherla, N., Kota, P., Dokholyan, N. V. & Asokan, A. Intra- and intersubunit disulfide bond formation is nonessential in adeno-associated viral capsids. PLoS One 7, e32163 (2012).
15. Pulicherla, N. et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 19, 1070-1078 (2011).
16. Lochrie, M. A. et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80, 821-834 (2006).
17. DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M. & Samulski, R. J. Surface loop dynamics in adeno-associated virus capsid assembly. J. Virol. 82, 5178-5189 (2008).
18. Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M. & Samulski, R. J. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 80, 8961-8969 (2006).
19. Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl Acad. Sci. USA 99, 10405-10410 (2002).
20. Nam, H. J. et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81, 12260-12271 (2007).
21. DiMattia, M. A. et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947-6958 (2012).
22. Govindasamy, L. et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80, 11556-11570 (2006).
23. Lerch, T. F., Xie, Q. & Chapman, M. S. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 403, 26-36 (2010).
24. Bell, C. L. et al. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121, 2427-2435 (2011).
25. Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H. & Asokan, A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286, 13532-13540 (2011).
26. O'Donnell, J., Taylor, K. A. & Chapman, M. S. Adeno-associated virus-2 and its primary cellular receptor-Cryo-EM structure of a heparin complex. Virology 385, 434-443 (2009).
27. Gurda, B. L. et al. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol. 86, 7739-7751 (2012).
28. McCraw, D. M., O'Donnell, J. K., Taylor, K. A., Stagg, S. M. & Chapman, M. S. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 431, 40-49 (2012).
29. Zhong, L. et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. USA 105, 7827-7832 (2008).
30. Dalkara, D. et al. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. 19, 176-181 (2012).
31. Qiao, C., Yuan, Z., Li, J., Tang, R. & Xiao, X. Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum. Gene Ther. Methods 23, 29-37 (2012).
32. Cheng, B. et al. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther. 19, 375-384 (2012).
33. Asokan, A. et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28, 79-82 (2010).
34. Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204 (2006).
35. Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887-5911 (2008).
36. Excoffon, K. J. et al. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc. Natl Acad. Sci. USA 106, 3865-3870 (2009).
37. Yang, L. et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl Acad. Sci. USA 106, 3946-3951 (2009).
38. Smith, A. M. et al. Quantitative phenotyping via deep barcode sequencing. Genome Res. 19, 1836-1842 (2009).
39. Wang, Z. et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321-328 (2005).
40. Inagaki, K. et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53 (2006).
41. Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080 (2008).
42. Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65 (2009).
43. Zhang, H. et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19, 1440-1448 (2011).
44. Kotchey, N. M. et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 19, 1079-1089 (2011).
45. Deutscher, S. L., Nuwayhid, N., Stanley, P., Briles, E. I. & Hirschberg, C. B. Translocation across Golgi vesicle membranes: a CHO glycosylation mutant deficient in CMP-sialic acid transport. Cell 39, 295-299 (1984).
46. Wu, Z., Miller, E., Agbandje-McKenna, M. & Samulski, R. J. α2,3 and α2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80, 9093-9103 (2006).
47. Walters, R. W. et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276, 20610-20616 (2001).
48. Gao, G. et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388 (2004).
49. Shen, S. et al. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J. Biol. Chem. 288, 28814-28823 (2013).
50. Lu, R., Neff, N. F., Quake, S. R. & Weissman, I. L. Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat. Biotechnol. 29, 928-933 (2011).
51. Patwardhan, R. P. et al. Massively parallel functional dissection of mammalian enhancers in vivo. Nat. Biotechnol. 30, 265-270 (2012).
52. Melnikov, A. et al. Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat. Biotechnol. 30, 271-277 (2012).
53. Matsushita, T. et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938-945 (1998).
54. Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232 (1998).
55. Burton, M. et al. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc. Natl Acad. Sci. USA 96, 12725-12730 (1999).
56. Grimm, D. et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102, 2412-2419 (2003).
57. Adachi, K. & Nakai, H. A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31-55 (2010).
58. Kawano, Y., Neeley, S., Adachi, K. & Nakai, H. An experimental and computational evolution-based method to study a mode of co-evolution of overlapping open reading frames in the AAV2 viral genome. PLoS One 8, e66211 (2013).
59. Glaser, F. et al. ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 19, 163-164 (2003).
60. Carrillo-Tripp, M. et al. VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 37, D436-D442 (2009).
61. R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing. ISBN 3-900051-07-0, http://www.R-project.org/, 2012).